reports
Snap Inc: 1 director
A director at Snap Inc sold 26,682 shares at 15.717USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Standard BioTools Reports First Quarter 2024 Financial Results
Standard BioTools Reports First Quarter 2024 Financial Results Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non-GAAP operating expense reduction of approximately $17 millionOn track to cash flow positive in full-year 2026 with current balance sheet of $464 million cash, cash equivalents, restricted cash and short-term invest...
- Wedbush Research
GEO GEO GROUP INC. (THE)
LOGN LOGITECH INTERNATIONAL S.A.
WAL WESTERN ALLIANCE BANCORP
SBUX STARBUCKS CORPORATION
RHP RYMAN HOSPITALITY PROPERTIES INC.
PEB PEBBLEBROOK HOTEL TRUST
GPRO GOPRO INC. CLASS A
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
EXLS EXLSERVICE HOLDINGS INC.
EWBC EAST WEST BANCORP INC.
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
OSTK OVERSTOCK.COM INC.
HST HOST HOTELS & RESORTS INC.
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
PK PARK HOTELS & RESORTS INC.
CELH CELSIUS HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
HEAR TURTLE BEACH CORP.
PRPL PURPLE INNOVATION
ARVN ARVINAS HOLDING
LYFT LYFT
GOSS GOSSAMER BIO
RVLV REVOLVE GROUP
IDYA IDEAYA BIOSCIENCES
CRSR CORSAIR GAMING
REAL REALCO
UPST UPSTART HOLDINGS
TWKS THOUGHTWORKS HOLDING
MQ MARQETA INC
JANX JANUX THERAPEUTICS INC
YOU CLEAR SECURE INC
VIGL VIGIL NEUROSCIENCE INC
HR HEALTHCARE TRUST OF AMERICA INC.
BROS DUTCH BROS INC
- Alicia Reese
- Brandon Barron
- Michael Pachter
- Dan Salmon
Snap Inc. (SNAP, Buy, raising target to $18 from $17) The roadmap for...
In this report, we briefly review six current drivers of SNAP’s direct response (DR) ad revenue growth, and five that could potentially contribute more in 2024. We also preview SNAP’s NewFront presentation tomorrow night, and update our model for last week’s earnings results, which result in our target increasing to $18 from $17 due to higher estimates and a higher target valuation.
- Wedbush Research
MTB M&T BANK CORPORATION
LOGN LOGITECH INTERNATIONAL S.A.
STZ CONSTELLATION BRANDS INC. CLASS A
UBI UBISOFT ENTERTAINMENT SA
DPZ DOMINO'S PIZZA INC.
WDC WESTERN DIGITAL CORPORATION
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PEGA PEGASYSTEMS INC.
MGPI MGP INGREDIENTS INC.
IMAX IMAX CORPORATION
GPRO GOPRO INC. CLASS A
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FHN FIRST HORIZON CORPORATION
EXPE EXPEDIA GROUP INC.
EPAM EPAM SYSTEMS INC.
DECK DECKERS OUTDOOR CORPORATION
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
OSTK OVERSTOCK.COM INC.
TMHC TAYLOR MORRISON HOME CORPORATION
HOPE HOPE BANCORP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
AMZN AMAZON.COM INC.
AAPL APPLE INC.
NKE NIKE INC. CLASS B
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
PRPL PURPLE INNOVATION
TENB TENABLE HOLDINGS
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
SOFI SOFI TECHNOLOGIES INC
YOU CLEAR SECURE INC
BROS DUTCH BROS INC
- Alicia Reese
- Brandon Barron
- Michael Pachter
- Dan Salmon
Snap Inc. (SNAP, Buy, $17 target) Everything works for the ad business
What’s New: In this first take following tonight’s results, we touch on: 1. Broad-based ad growth, and 85% SMB advertiser growth sticks out 2. Engagement metrics hold steady, keeping the biggest risk to the stock at bay 3. Snapchat+ now at 9M subscribers, nicely ahead of our 8.6M estimate for 1Q24 4. My AI and generative AI features lightly highlighted 5. 2024 non-GAAP expense guidance also given for the first time. 6. Timely share repurchases continue as SNAP better manages the share count
Seacoast Reports First Quarter 2024 Results
Seacoast Reports First Quarter 2024 Results Q1 Highlights Included Impressive Growth in Deposits, Successful Completion of Our Expense Initiative, and Building Wealth and Lending Pipelines Strong Capital Position Builds Quarter over Quarter STUART, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Seacoast Banking Corporation of Florida ("Seacoast" or the "Company") (NASDAQ: SBCF) today reported net income in the first quarter of 2024 of $26.0 million, or $0.31 per diluted share, compared to $29.5 million, or $0.35 per diluted share in the fourth quarter of 2023 and $11.8 million, or $0.15 per...
Standard BioTools Announces Operational Restructuring Plan to Drive Lo...
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while sup...
Standard BioTools Announces Conference Call and Webcast for First Quar...
Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on May 8, 2024, to discuss first quarter 2024 financial results and operational progress. A press release including...
- Dan Salmon
Snap Inc. (SNAP, Buy, raising target to $17 from $16) Quick Thoughts A...
What’s New: Ahead of Thursday PM’s earnings report, we review key controversies for SNAP, including: 1. Traction of SNAP’s direct response ad tech changes, and the trajectory of ad revenue growth. 2. Engagement levels in the North America, where deterioration is the most important risk this quarter. Also: can Global DAU growth hold +10%? 3. Flow through of the 10% headcount reduction in 1Q24, both on adjusted EBITDA margins and stock-based compensation. 4. We check in on SNAP’s non-advertising r...
Seacoast Banking Corporation of Florida Declares Quarterly Dividend on...
Seacoast Banking Corporation of Florida Declares Quarterly Dividend on Common Stock STUART, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- Seacoast Banking Corporation of Florida (“Seacoast” or the “Company”) (NASDAQ: SBCF), announced that on April 18, 2024, the Company’s Board of Directors declared a quarterly cash dividend to the holders of the Company’s common stock of $0.18 per share. The dividend is payable on June 28, 2024 to shareholders of record at the close of business on June 14, 2024. Seacoast Banking Corporation of Florida, through its wholly owned subsidiary Seacoast National Ban...
Standard BioTools Introduces New High-Throughput Multiplexed Whole Sli...
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging New advancements, including automation, aim to fast-forward spatial biology SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibility to the Imaging Mass Cytometry™ workflow on the Hyperion XTi™ Imaging System. Spatial biology is...
- Blair Levin
Standard BioTools Announces Multi-Year Strategic Engagement with Brist...
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with global biopharmaceutical company Bristol Myers Squibb for use of the SomaScan® Platform as a tool for clinical trials in multiple therapeutic areas through 2026. The SomaScan P...
- Wedbush Research
KMX CARMAX INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NCMI NATIONAL CINEMEDIA INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
IMAX IMAX CORPORATION
GPRO GOPRO INC. CLASS A
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CNK CINEMARK HOLDINGS INC.
CMRX CHIMERIX INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
DHI D.R. HORTON INC.
FRX_CN FENNEC PHARMACEUTICALS
PVH PVH CORP.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
FUBO FUBOTV
CURA CURALEAF HOLDINGS
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- Alicia Reese
- Matthew Weiss
- Michael Gerbino
- Michael Pachter
- Scott Devitt
Seacoast Banking Corporation of Florida to Announce First Quarter Earn...
Seacoast Banking Corporation of Florida to Announce First Quarter Earnings Results April 25, 2024 Investors May Listen to Live Webcast STUART, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- Seacoast Banking Corporation of Florida (NASDAQ: SBCF), a bank holding company whose operating entity is Seacoast Bank, today announced it will release first quarter 2024 results on April 25th, after the market closes. Upon release, investors may access a copy of Seacoast’s earnings results at the company’s website on the home page by selecting “Press Releases” under the heading “News/Events.” Seacoast ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.